least five business days in advance of the meeting. The meeting can be accessed from the NIH Videocast at the following link: *https://videocast.nih.gov/.*

Name of Committee: Scientific Advisory Committee on Alternative Toxicological Methods (SACATM).

Date: September 11–12, 2025.

Registration is required to attend to view the webcast, and/or present oral comments. Written public comments will be accepted. Information about the meeting, registration, and how to submit public comments are available at *https://ntp.niehs.nih.gov/go/32822.*

Time: 10:00 a.m. to approximately 3:15 p.m. Eastern Time (each meeting day)

Agenda: The preliminary agenda, registration, and other meeting materials will be available at *https://ntp.niehs.nih.gov/go/32822.*

Address: NIEHS Research Triangle Park, NC 27709 (Virtual Meeting).

Meeting Format: Virtual Meeting.

Contact Person: Mary S. Wolfe, Ph.D., Director, Office of Policy, Review, and Outreach, Division of Translational Toxicology, National Institute of Environmental Health Science, National Institutes of Health PO Box 12233, MD A3–01 111 T.W. Alexander Dr, Research Park Triangle, NC 27709, *wolfe@niehs.nih.gov.*

Any member of the public interested in presenting oral comments may register at *https://ntp.niehs.nih.gov/go/32822.* Each public comment period allows for five oral commenters. Only one representative of an organization may be allowed to present oral comments per comment period and if accepted by the committee, presentations are limited to five minutes. Registration is on a first-come, first-served basis. If the maximum number of commenters per comment period is exceeded, individuals registering to submit an oral comment will be placed on a wait list and notified should an opening become available.

In addition, any interested person may file written comments with the committee. Information on submitting written comment is available at *https://ntp.niehs.nih.gov/go/32822.*

Responses to this notice are voluntary. No proprietary, classified, confidential, or sensitive information should be included in statements submitted in response to this notice or presented during the meeting. This request for input is for planning purposes only and is not a solicitation for applications or an obligation on the part of the U.S. Government to provide support for any ideas identified in response to the request. Please note that the U.S. Government will not pay for the preparation of any information submitted or for its use of that information.

Additional information about SACATM, including link to the charter, roster, and records of past meetings, can be found at *https://ntp.niehs.nih.gov/go/advisory.*

Dated: July 1, 2025.

Bruce A. George,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2025–12480 Filed 7–2–25; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

FOR FURTHER INFORMATION CONTACT: Brian Bailey at 240–669–5128, or *bbailey@mail.nih.gov.* Licensing information may be obtained by communicating with the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852: tel. 301–496–2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention.

SUPPLEMENTARY INFORMATION: Technology description follows:

Anti-Nucleoprotein Crimean-Congo Hemorrhagic Fever Virus Monoclonal Antibodies for Assay Creation

Description of Technology

Crimean-Congo hemorrhagic fever (CCHF) is the most widespread form of viral hemorrhagic fever, found in Eastern and Southern Europe, the Mediterranean, northwestern China, central Asia, Africa, the Middle East, and the Indian subcontinent. Typically beginning with non-specific fever, myalgia, nausea, diarrhea, and general malaise, symptoms of infection with the tick-borne CCHF virus (CCHFV) can rapidly progress to hemorrhagic manifestations, with case fatality rates as high as 30–40% in some regions. Critically, there are no approved vaccines for CCHF, and prevention is limited to control of exposure to infected ticks and livestock.

Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Disease (NIAID) have recently demonstrated robust immunogenicity and significant protection in a Rhesus macaque model of CCHF following vaccination with a novel repRNA vaccine. Single memory B cells from peripheral blood mononuclear cells (PBMCs) were isolated from the vaccinated macaques to derive monoclonal antibodies that target the nucleocapsid protein (NP) of CCHFV, which plays a critical role in the replication and pathogenesis of the virus. This technology comprises mAbs with strong potential for the development of diagnostic tools, *in vitro* assays, research reagents, and other analytical methods for CCHFV NP recognition.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404.

Potential Commercial Applications:

- Development of diagnostic assays for rapid, accurate CCHFV detection in clinical and non-clinical settings.

Competitive Advantages:

- There are no readily available antibodies that bind to the NP protein of CCHFV.

Development Stage: Preclinical.

Relevant Publications: Hawman DW, et al. A replicating RNA vaccine confers protection in a rhesus macaque model of Crimean-Congo hemorrhagic fever. *NPJ Vaccines* 2024;9:86. *https://doi.org/10.1038/s41541-024-00887-z.*

Inventors: Daniel Douek, David Hawman, Leonid Serebryannyy, Noemia Santana Lima, Chaim Schramm, Sarah Smith (Kerscher), Amy Henry, Alicen Spaulding (all of NIAID)

Intellectual Property: HHS Reference No. E–129–2025.

Licensing Contact: To license this technology, please contact Brian Bailey at 240–669–5128, or *bbailey@mail.nih.gov,* and reference E–129–2025.

Dated: June 30, 2025.

Surekha Vathyam,

Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.

[FR Doc. 2025–12455 Filed 7–2–25; 8:45 am]

BILLING CODE 4140–01–P